** Shares of regenerative medicine company Orthocell OCC.AX rise 7.8% to A$1.390, set for biggest one-day gain since April 10
** Co says it has received regulatory approval to commence sales for its nerve repair product, Remplir, from the Food and Drug Administration in Thailand
** Stock on track for third consecutive session of gains
** Stock up 2.6% YTD, including current session's moves
(Reporting by Manasi Dasa in Bengaluru)
((Manasi.DasaSundeep@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.